GSK’s Trelegy Ellipta now approved for use in adults with uncontrolled asthma in China

GSK announces that China’s National Medical Products Administration has now approved a new indication for Trelegy Ellipta for the treatment of patients with asthma aged 18 years and older, adding to its current license for use in patients with chronic obstructive pulmonary disease. Note that this spproval was based on GSK’s CAPTAIN study which showed that in patients uncontrolled on inhaled corticosteroids/long-acting beta agonist the additional bronchodilation provided by FF/UMEC/VI demonstrated significant improvements in lung function compared with FF/VI.

Kaivan Khavandi, Senior Vice President, Global Head, Respiratory, Immunology and Inflammation, R&D said: “Early intervention with a single inhaler triple therapy can improve clinical outcomes for suitable patients with uncontrolled asthma. Today’s approval gives patients whose condition is not optimally managed, and therefore at increased risk of experiencing exacerbations, an important option in their care. As a company, we are committed to help change the course of disease and make clinical remission, where patients’ disease has sustained control, an ambitious but attainable treatment goal.”

---

---

Related Topics and Keywords

asthma, GSK, Trelegy Ellipta